サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1675301

MRSA治療薬市場：MRSAタイプ別、薬剤クラス別、適応疾患別、投与経路別、流通チャネル別、地域別、2025-2033年

MRSA Drugs Market by MRSA Type (Hospital-Acquired, Community-Acquired ), Drug Class, Disease Indication, Route of Administration, Distribution Channel, and Region 2025-2033

出版日
発行
IMARC
ページ情報
英文 142 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.08円
MRSA治療薬市場：MRSAタイプ別、薬剤クラス別、適応疾患別、投与経路別、流通チャネル別、地域別、2025-2033年
出版日: 2025年03月01日
発行: IMARC
ページ情報: 英文 142 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

MRSA治療薬市場の世界市場規模は2024年に39億米ドルに達しました。今後、IMARC Groupは、市場は2033年までに51億米ドルに達し、2025年から2033年にかけて2.95%の成長率（CAGR）を示すと予測しています。抗生物質耐性菌の蔓延、長期入院によるヘルスケア施設での多剤耐性菌への継続的な曝露、臨床試験数の増加が市場を牽引する主な要因のひとつです。

メチシリン耐性黄色ブドウ球菌（MRSA）は、抗生物質耐性の黄色ブドウ球菌株によって引き起こされる感染症で、一般に外科的処置を受けたり、静脈注射を受けたり、皮膚と皮膚を接触させたりした患者に発症します。MRSA治療薬は、メチシリン耐性黄色ブドウ球菌感染症に対する抗菌薬として使用され、黄色ブドウ球菌を死滅または抑制します。患者の細胞合成と免疫力を高めながら、病原体の作用を抑制します。最も一般的なMRSA治療薬は、トリメトプリム-スルファメトキサゾール、クリンダマイシン、ミノサイクリン、リネゾリド、ドキシサイクリンです。これらの薬剤は一般的に経口薬として使用され、通常7～10日間のコースで使用されます。MRSA感染症は病院や地域社会で発生する可能性があるため、MRSAの治療には、重症度に応じて経口薬や静脈内投与が行われることがあります。皮膚感染症、骨感染症、菌血症、さらには動物の人獣共通感染症など、さまざまなタイプの感染症の治療に使用できる多種多様なMRSA治療薬があります。

MRSA治療薬の市場動向：

大衆の間で抗生物質耐性株の開発が広まっていることは、市場の成長を促す重要な要因です。これは、世界レベルでの院内感染（HAI）の症例数の増加に起因しています。また、長期入院によるヘルスケア施設での多剤耐性菌への継続的な曝露が、二次的な院内感染の開発をもたらし、市場を促進しています。これに加えて、MRSA感染症を発症しやすい高齢者人口の増加が、市場に弾みをつけています。さらに、さまざまな形態の細菌感染に関する意識の高まりが、MRSA治療薬の普及につながっています。これに伴い、多くの製品イノベーション、臨床試験の増加、新薬の導入が市場に有利な成長機会をもたらしています。しかし、MRSA治療薬の新薬開発には高いコストがかかるため、市場の成長抑制要因となっています。これとは反対に、さまざまな診断ツールの継続的な技術開拓と、抗生物質耐性菌のスクリーニングのための臨床試験プログラムの増加が、市場の前向きな見通しを生み出しています。市場はさらに、主要企業が実施する広範な研究開発（R&D）活動が後押ししています。市場に貢献しているその他の要因としては、現在入手可能な製品に対するジェネリック医薬品の出現、オンラインおよびオフラインの組織化されたプラットフォームでの抗生物質の容易な入手、急速な都市化、医療費の増加などが挙げられます。

本レポートで扱う主な質問

  • 世界のMRSA治療薬の市場はこれまでどのように推移し、今後どのように推移するのか？
  • 世界のMRSA治療薬の市場における促進要因、抑制要因、機会は何か？
  • 主要な地域市場とは？
  • 最も魅力的なMRSA治療薬市場はどの国か？
  • MRSAタイプ別の市場内訳は？
  • 薬剤クラス別の市場内訳は？
  • 適応疾患別の市場内訳は？
  • 投与経路別の市場内訳は？
  • 流通チャネル別の市場内訳は？
  • 世界のMRSA治療薬の市場の競合構造は？
  • 世界のMRSA治療薬の市場における主要プレイヤー/企業は？

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査の目的
  • ステークホルダー
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要業界動向

第5章 世界のMRSA治療薬市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 市場内訳：MRSAタイプ別

  • 院内感染（HA-MRSA）
  • 市中感染（CA-MRSA）

第7章 市場内訳：薬剤クラス別

  • リポペプチド
  • オキサゾリジノン
  • セファロスポリン
  • テトラサイクリン
  • 葉酸拮抗薬
  • その他

第8章 市場内訳：適応疾患別

  • 皮膚感染症
  • 骨と関節の感染症
  • 菌血症
  • 動物の感染症

第9章 市場内訳：投与経路別

  • 経口投与
  • 非経口投与

第10章 市場内訳：流通チャネル別

  • 病院薬局
  • 小売薬局
  • オンライン薬局

第11章 市場内訳：地域別

  • 北米
    • 米国
    • カナダ
  • アジア太平洋地域
    • 中国
    • 日本
    • インド
    • 韓国
    • オーストラリア
    • インドネシア
    • その他
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • ロシア
    • その他
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • その他
  • 中東・アフリカ
    • 市場内訳：国別

第12章 促進要因・抑制要因・機会

  • 概要
  • 促進要因
  • 抑制要因
  • 機会

第13章 バリューチェーン分析

第14章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第15章 価格分析

第16章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • AbbVie Inc.
    • Basilea Pharmaceutica Ltd
    • Crystal Genomics Inc.
    • Cumberland Pharmaceuticals Inc
    • Melinta Therapeutics Inc
    • Paratek Pharmaceuticals, Inc.
    • Pfizer Inc
図表

List of Figures

  • Figure 1: Global: MRSA Drugs Market: Major Drivers and Challenges
  • Figure 2: Global: MRSA Drugs Market: Sales Value (in Billion USD), 2019-2024
  • Figure 3: Global: MRSA Drugs Market Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 4: Global: MRSA Drugs Market: Breakup by MRSA Type (in %), 2024
  • Figure 5: Global: MRSA Drugs Market: Breakup by Drug Class (in %), 2024
  • Figure 6: Global: MRSA Drugs Market: Breakup by Disease Indication (in %), 2024
  • Figure 7: Global: MRSA Drugs Market: Breakup by Route of Administration (in %), 2024
  • Figure 8: Global: MRSA Drugs Market: Breakup by Distribution Channel (in %), 2024
  • Figure 9: Global: MRSA Drugs Market: Breakup by Region (in %), 2024
  • Figure 10: Global: MRSA Drugs (Hospital-Acquired (HA-MRSA)) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 11: Global: MRSA Drugs (Hospital-Acquired (HA-MRSA)) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 12: Global: MRSA Drugs (Community-Acquired (CA-MRSA)) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 13: Global: MRSA Drugs (Community-Acquired (CA-MRSA)) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 14: Global: MRSA Drugs (Lipopeptides) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 15: Global: MRSA Drugs (Lipopeptides) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 16: Global: MRSA Drugs (Oxazolidinones) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 17: Global: MRSA Drugs (Oxazolidinones) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 18: Global: MRSA Drugs (Cephalosporin) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 19: Global: MRSA Drugs (Cephalosporin) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 20: Global: MRSA Drugs (Tetracycline) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 21: Global: MRSA Drugs (Tetracycline) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 22: Global: MRSA Drugs (Folate Antagonist) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 23: Global: MRSA Drugs (Folate Antagonist) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 24: Global: MRSA Drugs (Other Drug Classes) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 25: Global: MRSA Drugs (Other Drug Classes) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 26: Global: MRSA Drugs (Skin Infections) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 27: Global: MRSA Drugs (Skin Infections) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 28: Global: MRSA Drugs (Bone and Joint Infections) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 29: Global: MRSA Drugs (Bone and Joint Infections) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 30: Global: MRSA Drugs (Bacteremia) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 31: Global: MRSA Drugs (Bacteremia) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 32: Global: MRSA Drugs (Animal Infections) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 33: Global: MRSA Drugs (Animal Infections) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 34: Global: MRSA Drugs (Oral Administration) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 35: Global: MRSA Drugs (Oral Administration) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 36: Global: MRSA Drugs (Parenteral Administration) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 37: Global: MRSA Drugs (Parenteral Administration) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 38: Global: MRSA Drugs (Hospital Pharmacies) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 39: Global: MRSA Drugs (Hospital Pharmacies) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 40: Global: MRSA Drugs (Retail Pharmacies) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 41: Global: MRSA Drugs (Retail Pharmacies) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 42: Global: MRSA Drugs (Online Pharmacies) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 43: Global: MRSA Drugs (Online Pharmacies) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 44: North America: MRSA Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 45: North America: MRSA Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 46: United States: MRSA Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 47: United States: MRSA Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 48: Canada: MRSA Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 49: Canada: MRSA Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 50: Asia-Pacific: MRSA Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 51: Asia-Pacific: MRSA Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 52: China: MRSA Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 53: China: MRSA Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 54: Japan: MRSA Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 55: Japan: MRSA Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 56: India: MRSA Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 57: India: MRSA Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 58: South Korea: MRSA Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 59: South Korea: MRSA Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 60: Australia: MRSA Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 61: Australia: MRSA Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 62: Indonesia: MRSA Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 63: Indonesia: MRSA Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 64: Others: MRSA Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 65: Others: MRSA Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 66: Europe: MRSA Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 67: Europe: MRSA Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 68: Germany: MRSA Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 69: Germany: MRSA Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 70: France: MRSA Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 71: France: MRSA Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 72: United Kingdom: MRSA Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 73: United Kingdom: MRSA Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 74: Italy: MRSA Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 75: Italy: MRSA Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 76: Spain: MRSA Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 77: Spain: MRSA Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 78: Russia: MRSA Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 79: Russia: MRSA Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 80: Others: MRSA Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 81: Others: MRSA Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 82: Latin America: MRSA Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 83: Latin America: MRSA Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 84: Brazil: MRSA Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 85: Brazil: MRSA Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 86: Mexico: MRSA Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 87: Mexico: MRSA Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 88: Others: MRSA Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 89: Others: MRSA Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 90: Middle East and Africa: MRSA Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 91: Middle East and Africa: MRSA Drugs Market: Breakup by Country (in %), 2024
  • Figure 92: Middle East and Africa: MRSA Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 93: Global: MRSA Drugs Industry: Drivers, Restraints, and Opportunities
  • Figure 94: Global: MRSA Drugs Industry: Value Chain Analysis
  • Figure 95: Global: MRSA Drugs Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: MRSA Drugs Market: Key Industry Highlights, 2024 & 2033
  • Table 2: Global: MRSA Drugs Market Forecast: Breakup by MRSA Type (in Million USD), 2025-2033
  • Table 3: Global: MRSA Drugs Market Forecast: Breakup by Drug Class (in Million USD), 2025-2033
  • Table 4: Global: MRSA Drugs Market Forecast: Breakup by Disease Indication (in Million USD), 2025-2033
  • Table 5: Global: MRSA Drugs Market Forecast: Breakup by Route of Administration (in Million USD), 2025-2033
  • Table 6: Global: MRSA Drugs Market Forecast: Breakup by Distribution Channel (in Million USD), 2025-2033
  • Table 7: Global: MRSA Drugs Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 8: Global: MRSA Drugs Market: Competitive Structure
  • Table 9: Global: MRSA Drugs Market: Key Players
目次
Product Code: SR112025A6905

The global MRSA drugs market size reached USD 3.9 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 5.1 Billion by 2033, exhibiting a growth rate (CAGR) of 2.95% during 2025-2033. The rising prevalence of antibiotic resistant strains development, continual exposure to multidrug-resistant organisms in healthcare facilities due to prolonged hospital admission and the growing number of clinical trials represent some of the key factors driving the market.

Methicillin-resistant staphylococcus aureus (MRSA) is an infection caused by antibiotic-resistant strains of staphylococcus aureus that generally occurs in patients who undergo surgical procedures, receive intravenous tubing, or come in contact with each other skin-to-skin. The MRSA drugs are used as antimicrobial agents against methicillin-resistant staphylococcus aureus infection in order to kill or restrain it. They inhibit the actions of pathogens while enhancing the patient's cellular synthesis and immunity. The most common MRSA drugs consist of trimethoprim-sulfamethoxazole, clindamycin, minocycline, linezolid, or doxycycline. These drugs are generally used as oral medication, usually on a course of seven to ten days. MRSA infections can arise from hospitals or from community, hence the treatment for MRSA can sometimes involve the administration of oral medications and intravenous (IV) medications, depending on the severity. There are a wide variety of MRSA drugs available that can be used for the treatment of different types of infections, including skin infections, bone infections, bacteremia, and even zoonotic infections in animals.

MRSA Drugs Market Trends:

The rising prevalence of antibiotic resistant strains development among the masses is a significant factor driving the growth of the market. This can be attributed to the increase in the number of cases of hospital-acquired infections (HAIs) on the global level. Also, the continual exposure to multidrug-resistant organisms in healthcare facilities due to prolonged hospital admission is resulting in the development of secondary nosocomial infections, thereby propelling the market. In addition to this, the growing geriatric population that is more susceptible to developing MRSA infections is providing an impetus to the market. Moreover, the augmenting awareness regarding different forms of bacterial infection is leading to a higher uptake of MRSA drugs. In line with this, numerous product innovations, growing number of clinical trials and the introduction of novel drug variants are creating lucrative growth opportunities in the market. However, the high costs involved in developing novel MRSA drug variants is acting as major growth restraining-factor for the market. On the contrary, continual technological developments in various diagnostic tools, along with the increasing number of clinical trial programs for the screening of antibiotic resistant strains of bacteria, are creating a positive market outlook. The market is further impelled by extensive research and development (R&D) activities conducted by the key players. Some of the other factors contributing to the market include the emergence of generic drugs against presently available products, easy availability of antibiotics across online and offline organized platforms, rapid urbanization, and increasing medical expenditure.

Key Market Segmentation:

MRSA Type Insights

  • Hospital-Acquired (HA-MRSA)
  • Community-Acquired (CA-MRSA)

Drug Class Insights

  • Lipopeptides
  • Oxazolidinones
  • Cephalosporin
  • Tetracycline
  • Folate Antagonist
  • Others

Disease Indication Insights

  • Skin Infections
  • Bone and Joint Infections
  • Bacteremia
  • Animal Infections

Route of Administration Insights

  • Oral Administration
  • Parenteral Administration

Distribution Channel Insights

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Regional Insights:

  • North America
  • United States
  • Canada
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
  • Latin America
  • Brazil
  • Mexico
  • Others
  • Middle East and Africa
  • The report has also provided a comprehensive analysis of all the major regional markets that include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and Middle East and Africa. According to the report, North America was the largest market for MRSA drugs. Some of the factors driving the North America MRSA drugs market include the rising medical expenditure, the increasing number of clinical trial programs, extensive research and development (R&D) activities conducted by key players, etc.
  • Competitive Landscape
  • The report has also provided a comprehensive analysis of the competitive landscape in the global MRSA drugs market. Detailed profiles of all major companies have also been provided. Some of the companies covered include AbbVie Inc., Basilea Pharmaceutica Ltd, Crystal Genomics Inc., Cumberland Pharmaceuticals Inc., Melinta Therapeutics Inc, Paratek Pharmaceuticals, Inc., Pfizer Inc, etc.

Key Questions Answered in This Report:

  • How has the global MRSA drugs market performed so far and how will it perform in the coming years?
  • What are the drivers, restraints, and opportunities in the global MRSA drugs market?
  • What are the key regional markets?
  • Which countries represent the most attractive MRSA drugs markets?
  • What is the breakup of the market based on the MRSA type?
  • What is the breakup of the market based on the drug class?
  • What is the breakup of the market based on the disease indication?
  • What is the breakup of the market based on the route of administration?
  • What is the breakup of the market based on the distribution channel?
  • What is the competitive structure of the global MRSA drugs market?
  • Who are the key players/companies in the global MRSA drugs market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global MRSA Drugs Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by MRSA Type

  • 6.1 Hospital-Acquired (HA-MRSA)
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Community-Acquired (CA-MRSA)
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by Drug Class

  • 7.1 Lipopeptides
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Oxazolidinones
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Cephalosporin
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Tetracycline
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Folate Antagonist
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast
  • 7.6 Others
    • 7.6.1 Market Trends
    • 7.6.2 Market Forecast

8 Market Breakup by Disease Indication

  • 8.1 Skin Infections
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Bone and Joint Infections
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Bacteremia
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Animal Infections
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast

9 Market Breakup by Route of Administration

  • 9.1 Oral Administration
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Parenteral Administration
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast

10 Market Breakup by Distribution Channel

  • 10.1 Hospital Pharmacies
    • 10.1.1 Market Trends
    • 10.1.2 Market Forecast
  • 10.2 Retail Pharmacies
    • 10.2.1 Market Trends
    • 10.2.2 Market Forecast
  • 10.3 Online Pharmacies
    • 10.3.1 Market Trends
    • 10.3.2 Market Forecast

11 Market Breakup by Region

  • 11.1 North America
    • 11.1.1 United States
      • 11.1.1.1 Market Trends
      • 11.1.1.2 Market Forecast
    • 11.1.2 Canada
      • 11.1.2.1 Market Trends
      • 11.1.2.2 Market Forecast
  • 11.2 Asia-Pacific
    • 11.2.1 China
      • 11.2.1.1 Market Trends
      • 11.2.1.2 Market Forecast
    • 11.2.2 Japan
      • 11.2.2.1 Market Trends
      • 11.2.2.2 Market Forecast
    • 11.2.3 India
      • 11.2.3.1 Market Trends
      • 11.2.3.2 Market Forecast
    • 11.2.4 South Korea
      • 11.2.4.1 Market Trends
      • 11.2.4.2 Market Forecast
    • 11.2.5 Australia
      • 11.2.5.1 Market Trends
      • 11.2.5.2 Market Forecast
    • 11.2.6 Indonesia
      • 11.2.6.1 Market Trends
      • 11.2.6.2 Market Forecast
    • 11.2.7 Others
      • 11.2.7.1 Market Trends
      • 11.2.7.2 Market Forecast
  • 11.3 Europe
    • 11.3.1 Germany
      • 11.3.1.1 Market Trends
      • 11.3.1.2 Market Forecast
    • 11.3.2 France
      • 11.3.2.1 Market Trends
      • 11.3.2.2 Market Forecast
    • 11.3.3 United Kingdom
      • 11.3.3.1 Market Trends
      • 11.3.3.2 Market Forecast
    • 11.3.4 Italy
      • 11.3.4.1 Market Trends
      • 11.3.4.2 Market Forecast
    • 11.3.5 Spain
      • 11.3.5.1 Market Trends
      • 11.3.5.2 Market Forecast
    • 11.3.6 Russia
      • 11.3.6.1 Market Trends
      • 11.3.6.2 Market Forecast
    • 11.3.7 Others
      • 11.3.7.1 Market Trends
      • 11.3.7.2 Market Forecast
  • 11.4 Latin America
    • 11.4.1 Brazil
      • 11.4.1.1 Market Trends
      • 11.4.1.2 Market Forecast
    • 11.4.2 Mexico
      • 11.4.2.1 Market Trends
      • 11.4.2.2 Market Forecast
    • 11.4.3 Others
      • 11.4.3.1 Market Trends
      • 11.4.3.2 Market Forecast
  • 11.5 Middle East and Africa
    • 11.5.1 Market Trends
    • 11.5.2 Market Breakup by Country
    • 11.5.3 Market Forecast

12 Drivers, Restraints, and Opportunities

  • 12.1 Overview
  • 12.2 Drivers
  • 12.3 Restraints
  • 12.4 Opportunities

13 Value Chain Analysis

14 Porters Five Forces Analysis

  • 14.1 Overview
  • 14.2 Bargaining Power of Buyers
  • 14.3 Bargaining Power of Suppliers
  • 14.4 Degree of Competition
  • 14.5 Threat of New Entrants
  • 14.6 Threat of Substitutes

15 Price Analysis

16 Competitive Landscape

  • 16.1 Market Structure
  • 16.2 Key Players
  • 16.3 Profiles of Key Players
    • 16.3.1 AbbVie Inc.
      • 16.3.1.1 Company Overview
      • 16.3.1.2 Product Portfolio
      • 16.3.1.3 Financials
      • 16.3.1.4 SWOT Analysis
    • 16.3.2 Basilea Pharmaceutica Ltd
      • 16.3.2.1 Company Overview
      • 16.3.2.2 Product Portfolio
    • 16.3.3 Crystal Genomics Inc.
      • 16.3.3.1 Company Overview
      • 16.3.3.2 Product Portfolio
      • 16.3.3.3 Financials
    • 16.3.4 Cumberland Pharmaceuticals Inc
      • 16.3.4.1 Company Overview
      • 16.3.4.2 Product Portfolio
      • 16.3.4.3 Financials
    • 16.3.5 Melinta Therapeutics Inc
      • 16.3.5.1 Company Overview
      • 16.3.5.2 Product Portfolio
      • 16.3.5.3 Financials
    • 16.3.6 Paratek Pharmaceuticals, Inc.
      • 16.3.6.1 Company Overview
      • 16.3.6.2 Product Portfolio
      • 16.3.6.3 Financials
      • 16.3.6.4 SWOT Analysis
    • 16.3.7 Pfizer Inc
      • 16.3.7.1 Company Overview
      • 16.3.7.2 Product Portfolio
      • 16.3.7.3 Financials
      • 16.3.7.4 SWOT Analysis

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.